Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1406-1415

  Alvarez, Susana ^a   Germain, Pierre ^a   Alvarez, Rosana ^a   Rodríguez Barrios, Fátima ^a   Gronemeyer, Hinrich ^a   de Lera, Angel R ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Agonist; Cancer; Ligands; Retinoid receptors; Structure

Indexed keywords

ALITRETINOIN; HETERODIMER; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; LIGAND; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID X RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

BIOLOGICAL ACTIVITY; CANCER INHIBITION; GENETIC TRANSCRIPTION; HUMAN; KIDNEY CARCINOMA; LEUKOPLAKIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

BINDING SITES; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, TERTIARY; RECEPTORS, RETINOIC ACID; TRANS-ACTIVATION (GENETICS);

EID: 34447108899     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.02.010     Document Type: Review

References (66)

1. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
2. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., and Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7 (2001) 680-686
3. Blondel A., Renaud J.-P., Fischer S., Moras D., and Karplus M. Retinoic acid receptor: A simulation analysis of retinoic acid binding and the resulting conformational changes. J. Mol. Biol. 291 (1999) 101-115
4. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21 (2000) 381-388
5. Bourguet W., Ruff M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 375 (1995) 377-382
6. Bourguet W., Vivat V., Wurtz J.-M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5 (2000) 289-298
7. Carlsson P., Burendahl S., and Nilsson L. Unbinding of retinoic acid from the retinoic acid receptor by random expulsion molecular dynamics. Biophys. J. 91 (2006) 3151-3161
8. Castillo L., Milano G., Santini J., Demard F., and Pierrefite V. Analysis of retinoic acid receptor beta expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method. Clin. Cancer Res. 3 (1997) 2137-2142
9. Charpentier B., Bernardon J.-M., Eustache J., Millois C., Martin B., Michel S., et al. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 38 (1995) 4993-5006
10. Chen G.-Q., Lin B., Dawson M.I., and Zhang X.-K. Nicotine modulates the effects of retinoids on growth inhibition and RARb expression in lng cancer cells. Int. J. Cancer 99 (2002) 171-178
11. Chen J., Makino C.L., Peachey N.S., Baylor D.A., and Simon M.I. Mechanism of rhodopsin inactivation in vivo as revealed by the COOH-terminal truncation mutant. Science 267 (1995) 374-377
12. Clarke N., Jimenez-Lara A.M., Voltz E., and Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23 (2004) 3051-3060
13. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
14. Dolle P., Ruberte E., Leroy P., Morriss-Kay G., and Chambon P. Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis. Development 124 (1990) 1133-1151
15. Dundas J., Ouyang Z., Tseng J., Binkowski A., Turpaz Y., and Liang J. CASTp: Computed atas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucl. Acids Res. 34 (2006) W116-W118
16. Ebisawa M., Umemiya H., Ohta K., Fukasawa H., Kawachi E., Christoffel G., et al. Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem. Pharm. Bull. 47 (1999) 1778-1786
17. Egea P.F., Mitschler A., Rochel N., Ruff M., Chambon P., and Moras D. Crystal structure of the human RXRa ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J. 19 (2000) 2592-2601
18. Farboud B., Hauksdottir H., Wu Y., and Privalsky M.L. Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression. Mol. Cell. Biol. 23 (2003) 2844-2858
19. Faria T.N., Mendelsohn C., Chambon P., and Gudas L.J. The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J. Biol. Chem. 274 (1999) 26783-26788
20. Geisen C., Denk C., Küpper J.-H., and Schwarz E. Growth inhibition of cervical cancer cells by the human retinoic acid receptor gene. Int. J. Cancer 85 (2000) 289-295
21. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., et al. The pharmacology and classification of the nuclear receptor superfamily. Retinoic acid receptors (RARs). Pharmacol. Rev. 58 (2006) 712-725
22. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., et al. The pharmacology and classification of the nuclear receptor superfamily. Retinoid X receptors (RXRs). Pharmacol. Rev. 58 (2006) 760-772
23. Germain P., Iyer J., Zechel C., and Gronemeyer H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415 (2002) 187-192
24. Germain, P., Klemmerer, S., Pérez, E., Peluso-Iltis, C., Tortolani, D., Zusi, F. C., et al. (2004). Rational design of RAR selective ligands revealed by RARb crystal structure. EMBO Rep.
25. Germain P., Staels B., Dacquet C., Spedding M., and Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58 (2006) 685-704
26. Grondona J.M., Kastner P., Gansmuller A., Decimo D., Chambon P., and Mark M. Retinal dysplasia and degeneration in RARbeta2/RARgamma2 compound mutant mice. Development 122 (1996) 2173-2188
27. Gronemeyer H., Gustafsson J.-A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Disc. 3 (2004) 950-964
28. Gèhin M., Vivat V., Wurtz J.-M., Losson R., Chambon P., Moras D., et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol. 6 (1999) 519-529
29. Hashimoto Y., and Miyachi H. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. Bioorg. Med. Chem. 13 (2005) 5080-5093
30. Hauksdottir H., Farboud B., and Privalsky M.L. Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol. Endocrinol. 17 (2003) 373-385
31. Houle B., Rochette-Egly C., and Bradley W.E.C. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA 90 (1993) 985-989
32. James S.Y., Lin F., Kolluri S.K., Dawson M.I., and Zhang X.-k. Regulation of retinoic acid receptor β expression by peroxisome proliferator-activated receptor ligands in cancer cells. Cancer Res. 63 (2003) 3531-3538
33. Johnson A.T., Klein E.S., Gillett S.J., Wang L., Song T.K., Pino M.E., et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J. Med. Chem. 1995 (1996) 4764-4767
34. Klaholz B.P., Mitschler A., and Moras D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302 (2000) 155-170
35. Klaholz B.P., Renaud J.-P., Mitschler A., Zusi C., Chambon P., Gronemeyer H., et al. Conformational adaptation of agonists to the human nuclear receptor RARg. Nat. Struct. Biol. 5 (1998) 199-202
36. Kostzin D., Izrailev S., and Schulten K. Unbinding of retinoic acid from its receptor studied by steered molecular dynamics. Biophys. J. 76 (1999) 188-197
37. Krezel W., Ghyselinck N., Samad T.A., Dupe V., Kastner P., Borrelli E., et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 279 (1998) 863-867
38. Kumar S., Ma B.Y., Tsai C.J., Sinha N., and Nussinov R. Floding and binding cascades: Dynamic landscapes and population shifts. Protein Sci. 9 (2000) 10-19
39. Laudet V., and Gronemeyer H. The nuclear receptor facts book (2002), Academic Press, San Diego
40. Lotan R., Xu X.C., Lippman S.M., Ro J.Y., Lee J.S., Lee J.J., et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med. 332 (1995) 1405-1410
41. Lund B.W., Piu F., Gauthier N.K., Eeg A., Currier E., Sherbukhin V., et al. Discovery of a potent, orally available, and isoform-selective retinoic acid b2 receptor agonist. J. Med. Chem. 48 (2005) 7517-7519
42. Mark M., Ghyselinck N., and Chambon P. Function of retinoid nuclear receptors: Lessons from genetic and pharmacological dissections of the retinoic acid signalling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 451-480
43. Mark M., Ghyselinck N.B., and Chambon P. Retinoic acid signalling in the development of branchial arches. Curr. Opin. Genet. Dev. 14 (2004) 591-598
44. Nagy L., and Schwabe J.W.R. Mechanism of the nuclear receptor molecular switch. Trends Biomed. Sci. 29 (2004) 317-324
45. Pavri R., Lewis B., Kim T.K., Dilworth F.J., Erdjument-Bromage H., Tempst P., et al. PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol. Cell 18 (2005) 83-96
46. Petty W.J., Li N., Biddle A., Bounds R., Nitkin C., Ma Y., et al. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J. Natl. Cancer Inst. 97 (2005) 1645-1651
47. Picard E., Seguin C., Monhoven N., Rochette-Egly C., Siat J., Borrelly J., et al. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J. Natl. Cancer Inst. 91 (1999) 1059-1066
48. Pogenberg V., Guichou J.-F., Vivat-Hannah V., Kammerer S., Pérez E., Germain P., et al. Characterization of the interaction between RAR/RXR heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J. Biol. Chem. 280 (2005) 1625-1633
49. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., et al. Crystal Structure of the RAR-g ligand-binding domain bound to all-trans-retinoic acid. Nature 378 (1995) 681-689
50. Schapira M., Raaka B.M., Samuels H.H., and Abagyan R. In silico discovery of novel retinoic acid receptor agonist structures. BMC Struct. Biol. 1 (2001) 1-8
51. Seewaldt V.L., Johnson B.S., Parker M.B., Collins S.J., and Swisshelm K. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Diff. 6 (1995) 1077-1088
52. Sirchia S.M., Ren M., Pili R., Sironi E., Somenzi G., Ghidoni R., et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62 (2002) 2455-2461
53. Sommer K.M., Chen L., Treuting P.M., Smith L.T., and Swisshelm K. Elevated retinoic acid receptor beta(4) protein in human breast tumor cells with nuclear and cytoplasmic localization. Proc. Natl. Acad. Sci. USA 96 (1999) 8651-8656
54. Sun S.Y., and Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hemtal. 41 (2002) 41-55
55. Sun S.-Y., Wan H., Yue P., Hong W.K., and Lotan R. Evidence that retinoic acid receptor induction by retinoids is important for tumor cell growth inhibition. J. Biol. Chem. 275 (2000) 17149-17153
56. Sun S.Y., Yue P., Dawson M.I., Shroot B., Michel S., Lamph W.W., et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 57 (1997) 4931-4939
57. Thacher S.M., Vasaudevan J., and Chandraratna R.A.S. Therapeutic applications for ligands of retinoid receptors. Cur. Pharm. Des. 6 (2000) 25-58
58. Touma S.E., Goldberg J.S., Moench P., Guo X., Tickoo S.K., Gudas L.J., et al. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin. Cancer Res. 11 (2005) 3558-3566
59. TRAIL. In: Gerald L. (Ed). Vitamins and Hormones Vol. 67 (2004), Academic Press (Elsevier), New York
60. Umemiya H., Kagechika H., Fukasawa H., Kawachi E., Ebisawa M., Hashimoto Y., et al. A mechanism of retinoid-synergistic dibenzodiazepines. Biochem. Biophys. Res. Commun. 233 (1997) 121-125
61. Wang X.-F., Qian D.Z., Ren M., Kato Y., Wei Y., Zhang L., et al. Epigenetic modulation of retinoic acid receptor ß2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res. 11 (2005) 3535-3542
62. Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 57 (1997) 4158-4161
63. Widschwendter M., Berger J., Muller H.M., Zeimet A.G., and Marth C. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J. Mammary Gland Biol. Neoplasia 6 (2001) 193-201
64. Xu X.C., Sozzi G., Lee J.S., Lee J.J., Pastorino U., Pilotti S., et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J. Natl. Cancer Inst. 89 (1997) 624-629
65. Zelent A., Mendelsohn C., Kastner P., Krust A., Garnier J.M., Ruffenach F., et al. Differentially expressed isoforms of the mouse retinoic acid receptor beta generated by usage of two promoters and alternative splicing. EMBO J. 10 (1991) 71-81
66. Zusi F.C., Vivat-Hannah V., and Lorenzi M.V. Selective retinoids and rexinoids: Potential agents for cancer therapy and chemoprevention. Drug Discov. Today 7 (2002) 1165-1174